Aim To investigate association of two LPIN1 gene variations with main traits of metabolic syndrome (MS) (waist circumference, body mass index, blood pressure, triglycerides, HDL-cholesterol and fasting glucose levels) in population from Bosnia and Herzegovina. Methods This study included 43 patients with metabolic syndrome and 43 healthy controls from General Hospital in Tešanj, Bosnia and Herzegovina. Subjects were genotyped for two LPIN1 gene variations (rs11693809: C>T and rs2716610: C>T) by real time PCR method. Results In control subjects LPIN1 polymorphism, rs2716610: C>T, was significantly associated with a lower body mass index (BMI) (p=0.008) and waist circumference (p=0.008). The second analyzed rs11693809: C>T polymorphism was associated with lower blood HbA1c levels (p=0.048) in a group of MS patients. Conclusion Results of our study suggest that rs2716610: C>T polymorphism of LPIN1 gene could have a protective effect against development of metabolic syndrome, while rs11693809: C>T might affect a glucose control in patients with MS.
Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988. p. 1595–607.
4.
Defronzo R, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991. p. 173–94.
5.
Kaplan N. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989. p. 1514–20.
6.
Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet. 2005. p. 1415–28.
7.
Grundy S. Metabolic syndrome pandemic. Arterioscler Thromb Vasc. Biol. 2008. p. 629–36.
8.
Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute. Circulation. International Atherosclerosis Society; and International Association for the Study of Obesity; 2009. p. 1640–5.
9.
Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B, et al. Diagnosis and management of the metabolic syndrome: an. Circulation. American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement; 2005. p. 2735–52.
10.
Donkor J, Sariahmetoglu M, Dewald J, Brindley D, Reue K. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem. 2007. p. 3450–7.
11.
Rankinen T, Zuberi A, Chagnon Y, Weisnagel S, Argyropoulos G, Walts B, et al. The human obesity gene map: the 2005 update. Obesity (Silver Spring). 2006. p. 529–644.
12.
Peterfy M, Phan J, Xu P, Reue K. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet. 2001. p. 121–4.
13.
Peterfy M, Phan J, Reue K. Alternatively spliced lipin isoforms exhibit distinct expression pattern, subcellular localization, and role in adipogenesis. J Biol Chem. 2005. p. 32883–9.
14.
Phan J, Reue K. Lipin, a lipodystrophy and obesity gene. Cell Metab. 2005. p. 73–83.
15.
Reue K, Dwyer J. Lipin proteins and metabolic homeostasis. J Lipid Res. 2009. p. 109–14.
16.
Donkor J, Sparks L, Xie H, Smith S, Reue K. Adipose tissue lipin-1 expression is correlated with peroxisome proliferator-activated receptor alpha gene expression and insulin sensitivity in healthy young men. J Clin Endocrinol Metab. 2008. p. 233–9.
17.
Croce M, Eagon J, Lariviere L, Korenblat K, Klein S, Finck B. Hepatic lipin 1beta expression is diminished in insulin-resistant obese subjects and is reactivated by marked weight loss. Diabetes. 2007. p. 2395–9.
18.
Van Harmelen V, Ryden M, Sjolin E, Hoffstedt J. A role of lipin in human obesity and insulin resistance: relation to adipocyte glucose transport and GLUT4 expression. J Lipid Res. 2007. p. 201–6.
19.
Suviolahti E, Reue K, Cantor R, Phan J, Gentile M, Naukkarinen J, et al. Cross-species analyses implicate Lipin 1 involvement in human glucose metabolism. Hum Mol Genet. 2006. p. 377–86.
20.
Loos R, Rankinen T, Perusse L, Tremblay A, Despres J, Bouchard C. Association of lipin 1 gene polymorphisms with measures of energy and glucose metabolism. Obesity (Silver Spring). 2007. p. 2723–32.
21.
Cao H, Hegele R. Identification of single-nucleotide polymorphisms in the human LPIN1 gene. J Hum Genet. 2002. p. 370–2.
22.
Fawcett K, Grimsey N, Loos R, Wheeler E, Daly A, Soos M, et al. Evaluating the role of LPIN1 variation in insulin resistance, body weight, and human lipodystrophy in U.K. Populations. Diabetes. 2008. p. 2527–33.
23.
Ong K, Leung R, Wong L, Cherny S, Sham P, Lam T, et al. Association of a polymorphism in the lipin 1 gene with systolic blood pressure in men. Am J Hypertens. 2008. p. 539–45.
24.
Wiedmann S, Fischer M, Koehler M, Neureuther K, Riegger G, Doering A, et al. Genetic variants within the LPIN1 gene, encoding lipin, are influencing phenotypes of the metabolic syndrome in humans. Diabetes. 2008. p. 209–17.
25.
Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. p. 412–9.
26.
Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988. p. 1215.
27.
Zhao J. 2LD, GENECOUNTING and HAP: Computer programs for linkage disequilibrium analysis. Bioinformatics. 2004. p. 1325–6.
28.
Stephens M, Smith N, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001. p. 978–89.
29.
Bego T, Dujic T, Mlinar B, Semiz S, Malenica M, Prnjavorac B, et al. Association of PPARG and LPIN1 gene polymorphisms with metabolic syndrome and type 2 diabetes. Med Glas Ljek komore Zenicko-doboj kantona. 2011. p. 76–83.
30.
Mlinar B, Ferk P, Pfeifer M, Gersak K, Marc J. Lipin 1 gene polymorphisms in polycystic ovary syndrome. Horm Metab Res. 2011. p. 427–32.
31.
Forlani G, Bonito D, Mannucci P, Capaldo E, Genovese B, Orrasch S, et al. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest. 2008. p. 146–52.
32.
Marchesini G, Avagnina S, Barantani E, Ciccarone A, Corica F, Dall’aglio E, et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 2005. p. 333–9.
33.
Zhang Y, Lu X, Hong J, Chao M, Gu W, Wang W, et al. Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus. Endocrine. 2010. p. 181–7.
34.
Lal S, Sukla Y, Singh A, Andriyas A, Lall M. Hyperuricemia, high serum urea and hypoproteinemia are the risk facror for diabetes. Asian Journal of Medical Sciences. 2009. p. 33–4.
35.
Idonije B, Festus O, Oluba M. Plasma glucose, creatinine and urea levels in type 2 diabetic patients attending a Nigerian Teaching Hospital. Research Journal of Medical Sciences. 2011. p. 1–3.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
